RE: Belite Bio Inc (BLTE.US)23 May 2026 22:14
Belite Bio declined over the past month despite a significant Q1 earnings beat. This movement was driven by technical resistance and increased operating expenses. Sentiment suggests a positive quarter ahead as analysts project substantial upside following the company's New Drug Application submission and strong cash position of approximately $799 million.
.....................................................................................................................